Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Hypotension, Cerebral Blood Flow, Blood Pressure, Venous Occlusion Plethysmography
Conditions
Brief summary
While treatment strategies for OH have been identified for use in persons with acute SCI, the field of SCI medicine lacks a gold standard for treatment thresholds and well-defined outcome parameters. Comprehensively documenting the impact of orthostatic hypotension (OH), regardless of symptoms, during acute rehabilitation and identifying the effects of two different treatment approaches on therapy participation and adherence to an intended rehabilitation plan could have a significant impact on clinical practice in the acute rehabilitation setting following SCI.
Detailed description
Baseline Testing: Subjects will visit the testing laboratory on the SCI Rehabilitation Unit for baseline data collection, prior to initiation of the treatment protocol. Upon arrival, subjects will be placed in the supine position on an adjustable surface for instrumentation, which will be conducted in a quiet, dimly lit, thermo-neutral testing environment. After a 20-minute period of quiet rest, a 10-minute sample of supine heart rate (HR), respiratory rate, BP and CBF velocity data will be collected. Venous occlusion plethysmography (Vop) will be collected in the supine position for two 5-minute periods. After the supine data collection, subjects will be passively moved into the seated position, with the knees and hips at 90°, for the 10-minute seated data collection period. Subjects will be asked to complete two surveys related to AD and OH symptomology. Finally, subjects will be fitted with a 24-hour HR and BP monitor and will be asked to go about their normal routine. A record of all daily activities including rehabilitation, medications, eating and sleep/wake times will be logged. This testing session should take approximately 1 hour. Daily Testing: Every day supine and seated BP measurements will be performed at least three times per day. These BP assessments will be recorded in the supine and seated positions in the subject's room by a patient care associate who is blind to the study arm allocation. For every scheduled physical and occupational therapy session, the treating therapist will be asked to complete a brief 6 question survey to document if that session was altered, disrupted, or missed due to hypotension (Therapist Reported Version). The subject will also be asked to complete a brief survey to determine if from their perspective the session was altered, disrupted or missed due to hypotension (Subject Reported Version). In addition, every day a co-investigator and the attending physician for that subject will complete an EMR review of queried BP values within the previous 24 hours, symptoms of low BP, adverse events related to high or low BP, and will review (and act upon for the usual care arm) the protocol treatment decision tree. Weekly Testing: At weekly intervals of between 6 and 8 days, subjects will be asked to visit the testing laboratory on the SCI Rehabilitation Unit. Procedures for the weekly testing sessions will be the same as for the Baseline Testing. The 24-hour BP assessment will be conducted twice weekly. Discharge Testing: At discharge subjects will undergo similar testing as described during the Baseline and Weekly Testing with the addition of the Patient Global Impression of Change survey, which will be administered by the Mount Sinai Site Research Assistant.
Interventions
Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
Sponsors
Study design
Masking description
Therapists administering rehabilitation will be blinded to the randomization of patients enrolled in the study.
Intervention model description
Newly injured individuals with SCI will be eligible to participate if they demonstrate hypotension (systolic blood pressure \</= 110 mmHg in males or \</= 100 mmHg in females) upon admission to acute in-patient rehabilitation at Mount Sinai Medical Center, New York, NY. Eligible participants will be randomized to usual care (administered anti-hypotensive therapy only if they demonstrate symptoms of hypotension: dizziness, lightheadedness, nausea, blurred vision, syncope) or treatment of hypotension based on a systolic blood pressure below the hypotensive threshold. Time spent in active rehabilitation program will be compared between the usual care and treatment groups.
Eligibility
Inclusion criteria
* Any level of injury; * Any AIS grade of SCI; * Non-ventilator dependent * Primarily wheelchair dependent for mobility; * Duration of injury \< 1 year * Systolic BP less than 110 mmHg and/or diastolic BP less than 70 mmHg for males. * Systolic BP less than 100 mmHg and/or diastolic BP less than 70 mmHg for females * Primary Language is English. * Able to provide informed consent
Exclusion criteria
* Have insufficient mental capacity to independently provide informed consent * Have insufficient English speaking or reading ability to provide informed consent or complete assessments in English * Have contraindications to the use of midodrine hydrochloride * Are pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Affected Therapy Sessions | Inpatient hospitalization (up to 4 months) | Responses to the questions was the therapy session affected by low BP or concern for low BP development? between the usual care and BP threshold treatment groups. The percent of sessions with a yes response are reported. |
| Systolic Blood Pressure | Inpatient hospitalization (up to 4 months) | Systolic hypertension (\>/= 140 mmHg) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Systolic Blood Pressure | Inpatient Hospitalizations (up to 4 months) | Systolic hypotension (males: \< 110 mmHg; females: \< 100 mmHg) |
| Missed Therapy Sessions | Inpatient Hospitalizations (up to 4 months) | Percentages of missed therapy sessions, due to low BP or concern for low BP development, in the usual care and BP treatment groups |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Usual Care Group Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.
Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.).
Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine .
Midodrine Hydrochloride: Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d | 29 |
| BP Threshold Treatment Group Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay.
This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.).
If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg.
Midodrine Hydrochloride: Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d | 25 |
| Total | 54 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 4 | 8 |
Baseline characteristics
| Characteristic | BP Threshold Treatment Group | Total | Usual Care Group |
|---|---|---|---|
| Age, Categorical <=18 years | 1 Participants | 1 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 9 Participants | 6 Participants |
| Age, Categorical Between 18 and 65 years | 21 Participants | 44 Participants | 23 Participants |
| Age, Continuous | 41.97 years STANDARD_DEVIATION 15.84 | 43.89 years STANDARD_DEVIATION 16.67 | 45.82 years STANDARD_DEVIATION 17.49 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants | 8 Participants | 5 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants | 15 Participants | 8 Participants |
| Race (NIH/OMB) More than one race | 5 Participants | 11 Participants | 6 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 10 Participants | 20 Participants | 10 Participants |
| Region of Enrollment United States | 25 participants | 54 participants | 29 participants |
| Sex: Female, Male Female | 6 Participants | 11 Participants | 5 Participants |
| Sex: Female, Male Male | 19 Participants | 43 Participants | 24 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 29 | 0 / 25 |
| other Total, other adverse events | 0 / 29 | 0 / 25 |
| serious Total, serious adverse events | 0 / 29 | 0 / 25 |
Outcome results
Affected Therapy Sessions
Responses to the questions was the therapy session affected by low BP or concern for low BP development? between the usual care and BP threshold treatment groups. The percent of sessions with a yes response are reported.
Time frame: Inpatient hospitalization (up to 4 months)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Usual Care Group | Affected Therapy Sessions | 16.4 percentage of sessions |
| BP Threshold Treatment Group | Affected Therapy Sessions | 10.9 percentage of sessions |
Systolic Blood Pressure
Systolic hypertension (\>/= 140 mmHg)
Time frame: Inpatient hospitalization (up to 4 months)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Usual Care Group | Systolic Blood Pressure | 4.8 percentage of BP assessments |
| BP Threshold Treatment Group | Systolic Blood Pressure | 5.3 percentage of BP assessments |
Missed Therapy Sessions
Percentages of missed therapy sessions, due to low BP or concern for low BP development, in the usual care and BP treatment groups
Time frame: Inpatient Hospitalizations (up to 4 months)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Usual Care Group | Missed Therapy Sessions | 58.60 percentage of missed therapy sessions |
| BP Threshold Treatment Group | Missed Therapy Sessions | 65.8 percentage of missed therapy sessions |
Systolic Blood Pressure
Systolic hypotension (males: \< 110 mmHg; females: \< 100 mmHg)
Time frame: Inpatient Hospitalizations (up to 4 months)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Usual Care Group | Systolic Blood Pressure | 39.7 percentage of BP assessments |
| BP Threshold Treatment Group | Systolic Blood Pressure | 43.0 percentage of BP assessments |